Clinical Trial Update: Tofacitinib for Reduction of Spinal Inflammation in Patients With Psoriatic ArthritiS PresenTing With Axial InvOlvement [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tofacitinib for reducing spinal inflammation in psoriatic arthritis with axial involvement.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis
• Spondylitis

Drugs mentioned

• Tofacitinib (tofacitinib)

Snippet

Sponsor: Charite University, Berlin, Germany | Conditions: Psoriatic Arthritis, Spondylitis | Phase 2 | Status: UNKNOWN